Amneal Takes Control Of Kashiv Specialty In $100m+ Deal

Points To Value Of 505(b)(2) Pipeline And Complex Generics Experience

Amneal will take a majority stake in Kashiv Specialty Pharmaceuticals after striking a deal worth potentially more than $100m for a 98% stake in the hybrid 505(b)(2) and complex generics specialist.

Handshake
Amneal has agreed a deal to take a 98% stake in Kashiv Specialty • Source: Shutterstock

Amneal Pharmaceuticals is to take control of hybrid 505(b)(2) and complex generics specialist Kashiv Specialty Pharmaceuticals, after striking a deal that could be worth more than $100m for a 98% stakeholding.

Kashiv Specialty Pharmaceuticals is a subsidiary of Kashiv BioSciences, where Amneal co-CEO Chintu Patel previously served as CEO after the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business